ARTV

In the past six months, Artiva Biotherapeutics' stock has experienced significant movement. On May 8, 2026, Artiva announced the pricing of a $300 million underwritten public offering and reported its first-quarter 2026 financial results, with a net loss of $23.5 million, or $0.95 per share, which was wider than analysts' expectations. Also on May 8, 2026, Artiva announced positive initial clinical data for AlloNK® in refractory rheumatoid arthritis (RA) and received FDA alignment to initiate a Phase 3 registrational trial in RA in 2026. On March 10, 2026, the company reported full-year 2025 financial results and highlighted progress in its AlloNK program. On October 17, 2025, Artiva Biotherapeutics received FDA Fast Track designation for its first-in-class B-cell depleting therapy in refractory RA.